Banco Bilbao Vizcaya Argentaria, S.A. (0A2B)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 25.04 |
|---|---|
| 52-week range | 19.50 – 29.54 |
| Return, 1 month / 3 months | −11.3% / −3.1% |
| Return, 1 year / 3 years | +35.7% / +268.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 33 |
| Volatility (1 year) | 30.4% |
| Worst drawdown (1 year) | -20.9% |
| Average daily value traded | 0.51M USD |
| Dividend yield | 5.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Banco Bilbao Vizcaya Argentaria is a Spanish banking group based in Madrid. It offers retail and commercial banking, including current accounts, mortgages, consumer loans, savings products and payment services, to individuals and small businesses. It also serves larger companies and institutions with corporate lending, treasury and investment banking services. Its main markets are Spain, Mexico, Turkey and South America, where it operates through local banking brands and branch networks.
Banco Bilbao Vizcaya Argentaria, S.A. trades under the code 0A2B on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Banco Bilbao Vizcaya Argentaria, S.A. (0A2B) trades on the London Exchange in UK. It last closed at USD 25.04 on 22 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 1,031 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 35.7% and over the last three months it fell 3.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.1% | ||
| From 52-week high | -15.1% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -3.1% | ||
| 6-month return | 13.2% | ||
| 12-month return, skipping the last month | 52.9% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.9% | ||
| Liquidity | 46 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.51M USD | ||
| Zero-volume days | 1.7% | ||
| Income | 62 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.8% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.2% |
|---|---|
| 1 month | −11.3% |
| 3 months | −3.1% |
| 6 months | +13.2% |
| 1 year | +35.7% |
| 3 years | +268.7% |
| 5 years | +416.7% |
Signals
| 50-day / 200-day average | 27.65 / 24.29 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.52 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Oct 2026 | EUR 0.3376 |
| 9 Apr 2026 | EUR 0.5738 |
| 6 Nov 2025 | EUR 0.3695 |
| 9 Apr 2025 | EUR 0.4584 |
| 9 Oct 2024 | EUR 0.3161 |
| 8 Apr 2024 | EUR 0.4180 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.